Syntaxin’s TSI are novel recombinant proteins designed to exploit the unique pharmacology inherent in bacterial botulinum neurotoxins
View how it works >
Syntaxin is a leader in botulinum toxin biology and applies its expertise to the identification of new therapeutic opportunities
View Patient Focus >
15 July 2013
Ipsen strengthens its neurology R&D capabilities with the acquisition of Syntaxin, a leader in recombinant botulinum toxin technology
Ipsen (Euronext: IPN; ADR: IPSEY) announced today the closing of the a...
08 May 2013
Syntaxin Hosting Biological Safety: Management and Practice Open Training Course, 11-12 July 2013
Syntaxin Hosting Biological Safety: Management and Practice Open Train...
29 March 2012
Melanie Lee, CEO of Syntaxin, joins the Board of Lundbeck
Oxford (UK), 29 March 2012 - Syntaxin, a biotechnology company special...
View all news >
Find out more about the Ipsen Group
Copyright © Syntaxin 2010
Designed & developed by Emperor